.png){kind=icon}
.png){kind=icon}
Return
Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study
.png){kind=icon}
OA
AI
K
M
M
T
Y
S
K
J
N
J
S
N
N
Y
N
A
K
Y
K
H
DOI：10.1016/j.jtha.2026.06.012.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Long-term real-world outcomes of edoxaban in chronic thromboembolic pulmonary hypertension (CTEPH) remain incompletely characterised despite emerging evidence, including the KABUKI randomised trial.
Keywords:
Anticoagulants
chronic thromboembolic pulmonary hypertension
venous thromboembolism
direct oral anticoagulants
observational study
registries
BNP
brain natriuretic peptide
BPA
balloon pulmonary angioplasty
CI
confidence interval
CrCl
creatinine clearance
CTEPH
chronic thromboembolic pulmonary hypertension
DOAC
direct oral anticoagulant
FAS
full analysis set
ISTH
International Society on Thrombosis and Haemostasis
mPAP
mean pulmonary arterial pressure
PDE5
phosphodiesterase 5
PEA
pulmonary endarterectomy
PGI2
prostaglandin I2
PVR
pulmonary vascular resistance
sGC
soluble guanylate cyclase
VTE
venous thromboembolism
WHO
World Health Organization
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5
Papers:
9.8K
Citations:
2.3W
Organization
No organization information available
Cited Papers